Skip to content
International Academy for Clinical Hematology (IACH) Logo
  • About
    • Mission
    • Bylaws
    • Topics
    • Membership
    • Founders
    • Conflict of Interest Policy
    • Clinical Hematology International
    • IACH Supporters
    • Contact
    • Meetings
      • Controversies in Multiple Myeloma (COMy)
      • Controversies in MDS and AML (COMydAL)
      • Controversies in Lymphoma (COLYM)
      • MPNControversies & Debates (MPN Co&D)
      • Annual Meeting of the IACH
      • Summit on Immunotherapy and Cellular Therapy in Cancer (ICTC)
  • Webinars
    • Post-Cong. webinars
    • Special webinars
  • IACH Giants
  • Journal Club
  • IACH News
  • Junior Club
  • The Innovation and R&D Podium

Monzr Al Malki – The role of post cyclophosphamide, for GVHD prophylaxis, in the mismatched unrelated setting

Home/All/Monzr Al Malki – The role of post cyclophosphamide, for GVHD prophylaxis, in the mismatched unrelated setting
Previous Next

Monzr Al Malki – The role of post cyclophosphamide, for GVHD prophylaxis, in the mismatched unrelated setting

By Amnon Ron|2021-07-16T19:20:11+00:00July 16th, 2021|All|Comments Off on Monzr Al Malki – The role of post cyclophosphamide, for GVHD prophylaxis, in the mismatched unrelated setting

Share This Story, Choose Your Platform!

FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkEmail

About the Author: Amnon Ron

Related Posts

Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Prof. Florent Malard- The First microbiota therapy approved by the US FDA

Prof. Florent Malard- The First microbiota therapy approved by the US FDA

Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure

Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure

Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma

Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma

Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

About

The IACH, founded by an international group of physicians whose focus is to promote good clinical practice in the field of clinical hematology, is registered in England (Number: 14200227) under the Companies Act 2006.

In collaboration with:

Contact

International Academy for Clinical Hematology (IACH)
35 Ballards Lane
London N3 1XW
United-Kingdom
info@clinical-hematology.org
+44 203 291 1603

Copyright © 2022 International Academy for Clinical Hematology | All Rights Reserved
Page load link
Go to Top